Home > Insider Trading > Filing (0001104659-17-025040)

Filing Details

Accession Number:: 0001104659-17-025040
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-04-21 07:16:46
Reporting Period:: 2017-04-19

Filing Date:: 2017-04-21
Accepted Time:: 2017-04-21 07:16:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850261	Sorrento Therapeutics Inc.	SRNE	Services-Commercial Physical & Biological Research (8731)	330344842

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1609313	Ally Bridge Group Capital Partners Ii, L.p.	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1667354	Ltd Fund Master Healthcare Lb Bridge Ally	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1668027	Ltd Management Abg	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1668028	Ltd Management Lb Bridge Ally	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1668029	Fan Yu	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1668219	Bin Li	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1674513	Ally Bridge Group Innovation Capital Partners Iii, L.p.	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1676083	Ltd Srne Abg	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No
1676141	Ltd Ii-So Abg	Unit 3002-3004, 30Th Floor, Gloucester Tower, The Landmark, Central Hong Kong K3 00000	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-04-19	550,000	$2.00	1,991,441	No	4	P	Indirect	Through Ally Bridge LB Healthcare Master Fund Limited See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Through Ally Bridge LB Healthcare Master Fund Limited See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,397,853	Indirect	Through ABG II-SO Limited See footnote
Common Stock	3,243,242	Indirect	Through ABG SRNE Limited See footnote
Common Stock	1,500,000	Indirect	Through ABG Innovation-SO Limited See footnote

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants	$8.50	2019-05-31	432,432	432,432	Indirect
Common Stock	Warrants	$8.50	2019-05-31	432,432	432,432	Indirect
Common Stock	Warrants	$8.50	2019-06-07	540,540	540,540	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2019-05-31	432,432	432,432	Indirect
2019-05-31	432,432	432,432	Indirect
2019-06-07	540,540	540,540	Indirect

Footnotes

The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (ix) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
ABG II-SO directly owns 1,397,853 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
ABG LB directly owns (i) 1,991,441 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
ABG SRNE directly owns (i) 3,243,242 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
Ally Bridge Group Innovation Capital Partners III, L.P. is the owner of the sole voting share of ABG Innovation-SO Limited, a British Virgin Islands limited company, which directly owns 1,500,000 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
The warrants are exercisable at any time on or after May 31, 2016.
The warrants are exercisable at any time on or after June 7, 2016.